PATIENT SUPPORT
The TYVASO DPI 90-Day Trial Program allows you to assess the tolerability and efficacy of TYVASO DPI with your patients
- The program is offered to eligible patients at no cost for up to 90 days
- Your patients have no obligation to continue taking TYVASO DPI at the end of the trial period
- Eligibility for this program is limited to patients with PAH (WHO Group 1) or PH-ILD (WHO Group 3). This program is not valid for: patients currently using TYVASO DPI, Orenitram® (treprostinil) Extended-Release Tablets, TYVASO® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection; patients who previously used TYVASO DPI outside of the hospital setting; patients currently on an inhaled, oral, or infused prostacyclin. For other eligibility criteria, see full Terms and Conditions on the Enrollment Form
A Virtual Patient Educator is available to help your patients get started with TYVASO
The United Therapeutics’ Archways program is a virtual, educational support program that offers helpful disease information and resources for treatment. Archways is available at no cost to patients and caregivers as they begin their treatment journey with TYVASO.
To get started, patients may follow one of these three simple steps:
- Call 1-888-327-2492
- Text “START” to 882724 (Standard message and data rates may apply)
- Visit www.UTArchways.com
United Therapeutics and the Archways program do not provide medical advice. Patients are advised to consult with their HCP with any specific questions or concerns about their treatment.
Financial assistance
ASSIST provides access and financial assistance
- ASSIST helps patients determine if they qualify for United Therapeutics’ patient assistance programs
- Patients can contact an ASSIST advisor by calling 1-877-UNITHER (1-877-864-8437), Monday through Friday, 8:30 am to 7 pm ET
- Information for healthcare professionals is available at www.UTassist.com
Co-Pay Assistance Program*
With the TYVASO Co-Pay Assistance Program, most eligible patients pay as little as a $0 co-pay for each prescription of TYVASO or TYVASO DPI.
For full program details and Terms and Conditions, visit www.UTcopay.com.
*To enroll in this Program, your patients must understand and agree to comply with the eligibility requirements and terms of use.
Eligibility requirements for this Program are:
- Patients must be 18 years or older to use this Program.
- Patients using Medicare, Medicaid, or any other state or federal government program to pay for their medications are not eligible. Patients who start utilizing government coverage during the term of the Program will no longer be eligible.
- The Program is valid only for patients with commercial (also known as private) insurance who are taking the medication for an FDA-approved indication. The Program is only valid for the cost of the treprostinil product and not applicable to any related supplies or other medical expenses associated with administering the product.
- Eligible patients must be residents of the US or Puerto Rico. The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program.
DPI=dry powder inhaler; PAH=pulmonary arterial hypertension; WHO=World Health Organization.
The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals. If you are not a US healthcare professional, please click CLOSE to return to the consumer section of the site.